[Form 4] Jazz Pharmaceuticals, Inc. Insider Trading Activity
Patrick Enright, identified as a director of Jazz Pharmaceuticals (JAZZ), was granted 3,507 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one ordinary share and, subject to continued service and other conditions, the units will vest in full on July 24, 2026. The filing also reports a sale of 1,805 ordinary shares on 08/08/2025 at $111.2491 to satisfy tax obligations arising from the vesting of previously granted RSUs. The reported direct beneficial ownership rose to 28,184 shares following the RSU grant and declined to 26,379 shares after the tax-related sale.
Patrick Enright, indicato come amministratore di Jazz Pharmaceuticals (JAZZ), ha ricevuto 3.507 unit脿 di azioni vincolate (RSU) l'08/07/2025. Ogni RSU rappresenta il diritto condizionato a ricevere un'azione ordinarie e, soggetto al proseguimento del servizio e ad altre condizioni, le unit脿 matureranno integralmente il 24 luglio 2026. La comunicazione segnala inoltre la vendita di 1.805 azioni ordinarie l'08/08/2025 a $111,2491 per assolvere gli obblighi fiscali derivanti dalla maturazione di RSU precedentemente assegnate. La partecipazione diretta dichiarata 猫 salita a 28.184 azioni dopo l'assegnazione delle RSU e poi 猫 scesa a 26.379 azioni in seguito alla vendita per tasse.
Patrick Enright, identificado como director de Jazz Pharmaceuticals (JAZZ), recibi贸 3.507 unidades de acciones restringidas (RSU) el 08/07/2025. Cada RSU representa el derecho contingente a recibir una acci贸n ordinaria y, sujeto a la permanencia en el puesto y a otras condiciones, las unidades se consolidar谩n en su totalidad el 24 de julio de 2026. La presentaci贸n tambi茅n informa la venta de 1.805 acciones ordinarias el 08/08/2025 a $111,2491 para satisfacer obligaciones fiscales derivadas de la consolidaci贸n de RSU previamente otorgadas. La propiedad directa beneficiaria informada subi贸 a 28.184 acciones tras la concesi贸n de RSU y descendi贸 a 26.379 acciones despu茅s de la venta relacionada con impuestos.
Patrick Enright鞚� Jazz Pharmaceuticals (JAZZ)鞚� 鞚挫偓搿� 霌膘灛霅橃柎 3,507臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(RSU)毳� 08/07/2025鞐� 攵�鞐皼鞎橃姷雼堧嫟. 臧� RSU電� 氤错喌欤� 1欤茧ゼ 氚涭潉 靾� 鞛堧姅 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃橂┌, 瓿勳啀 攴茧 氚� 旮绊儉 臁瓣贝鞚� 於╈”霅橂┐ 頃措嫻 雼渼電� 2026雲� 7鞗� 24鞚�鞐� 鞝勲秬 旆摑霅╇媹雼�. 瓿奠嫓鞐愲姅 霕愴暅 鞚挫爠鞐� 攵�鞐悳 RSU鞚� 旆摑鞙茧 鞚疙暣 氚滌儩頃� 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 08/08/2025鞐� 1,805欤� 氤错喌欤�毳� 欤茧嫻 $111.2491鞐� 毵る弰頃� 靷嫟霃� 氤搓碃霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 歆侅爲 氤挫湢 欤检嫕靾橂姅 RSU 攵�鞐� 頉� 28,184欤�搿� 歃濌皜頄堧嫟臧� 靹戈笀 甏�霠� 毵り皝 頉� 26,379欤�搿� 臧愳唽頄堨姷雼堧嫟.
Patrick Enright, d茅sign茅 comme administrateur de Jazz Pharmaceuticals (JAZZ), s'est vu attribuer 3 507 unit茅s d'actions restreintes (RSU) le 08/07/2025. Chaque RSU repr茅sente un droit conditionnel 脿 recevoir une action ordinaire et, sous r茅serve de la permanence du service et d'autres conditions, les unit茅s deviendront pleinement acquises le 24 juillet 2026. Le d茅p么t signale 茅galement la vente de 1 805 actions ordinaires le 08/08/2025 脿 $111,2491 pour satisfaire les obligations fiscales r茅sultant de l'acquisition d'anciennes RSU. La propri茅t茅 b茅n茅ficiaire directe d茅clar茅e est pass茅e 脿 28 184 actions apr猫s l'attribution des RSU puis est retomb茅e 脿 26 379 actions apr猫s la vente li茅e aux imp么ts.
Patrick Enright, als Direktor von Jazz Pharmaceuticals (JAZZ) gef眉hrt, erhielt am 08/07/2025 3.507 Restricted Stock Units (RSU). Jede RSU stellt das bedingte Recht dar, eine Stammaktie zu erhalten, und unterliegt fortgesetzter Dienstzeit sowie weiteren Bedingungen; die Einheiten werden vollst盲ndig am 24. Juli 2026 f盲llig. Die Meldung berichtet ferner 眉ber den Verkauf von 1.805 Stammaktien am 08/08/2025 zu $111,2491, um steuerliche Verpflichtungen aus der Aus眉bung zuvor gew盲hrter RSUs zu erf眉llen. Das gemeldete direkte wirtschaftliche Eigentum stieg nach der RSU-Zuweisung auf 28.184 Aktien und sank nach dem steuerbedingten Verkauf auf 26.379 Aktien.
- None.
- None.
Insights
TL;DR: Routine director equity award and a tax-related disposition; governance alignment preserved, no new governance concerns disclosed.
The Form 4 shows a standard grant of restricted stock units to a non-employee director and a contemporaneous sale of shares to satisfy tax withholding. The RSUs vest on July 24, 2026, subject to continued service, which is a common retention and alignment mechanism for board members. The sale is described explicitly as a tax-related disposition of previously vested units. The filing does not disclose any change in board composition, new agreements, or governance exceptions.
TL;DR: Non-material insider grant and a tax-related sell-to-cover; reported holdings changed by a few thousand shares.
The reported transactions consist of a grant of 3,507 RSUs and a sale of 1,805 shares at $111.2491 for tax obligations. Reported direct beneficial ownership moved from 28,184 shares post-grant to 26,379 shares after the sale. The Form 4 does not report option exercises, pledges, or derivative positions. Based solely on the disclosed quantities and descriptions, these transactions are routine insider compensation and withholding actions documented under Section 16 reporting.
Patrick Enright, indicato come amministratore di Jazz Pharmaceuticals (JAZZ), ha ricevuto 3.507 unit脿 di azioni vincolate (RSU) l'08/07/2025. Ogni RSU rappresenta il diritto condizionato a ricevere un'azione ordinarie e, soggetto al proseguimento del servizio e ad altre condizioni, le unit脿 matureranno integralmente il 24 luglio 2026. La comunicazione segnala inoltre la vendita di 1.805 azioni ordinarie l'08/08/2025 a $111,2491 per assolvere gli obblighi fiscali derivanti dalla maturazione di RSU precedentemente assegnate. La partecipazione diretta dichiarata 猫 salita a 28.184 azioni dopo l'assegnazione delle RSU e poi 猫 scesa a 26.379 azioni in seguito alla vendita per tasse.
Patrick Enright, identificado como director de Jazz Pharmaceuticals (JAZZ), recibi贸 3.507 unidades de acciones restringidas (RSU) el 08/07/2025. Cada RSU representa el derecho contingente a recibir una acci贸n ordinaria y, sujeto a la permanencia en el puesto y a otras condiciones, las unidades se consolidar谩n en su totalidad el 24 de julio de 2026. La presentaci贸n tambi茅n informa la venta de 1.805 acciones ordinarias el 08/08/2025 a $111,2491 para satisfacer obligaciones fiscales derivadas de la consolidaci贸n de RSU previamente otorgadas. La propiedad directa beneficiaria informada subi贸 a 28.184 acciones tras la concesi贸n de RSU y descendi贸 a 26.379 acciones despu茅s de la venta relacionada con impuestos.
Patrick Enright鞚� Jazz Pharmaceuticals (JAZZ)鞚� 鞚挫偓搿� 霌膘灛霅橃柎 3,507臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(RSU)毳� 08/07/2025鞐� 攵�鞐皼鞎橃姷雼堧嫟. 臧� RSU電� 氤错喌欤� 1欤茧ゼ 氚涭潉 靾� 鞛堧姅 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃橂┌, 瓿勳啀 攴茧 氚� 旮绊儉 臁瓣贝鞚� 於╈”霅橂┐ 頃措嫻 雼渼電� 2026雲� 7鞗� 24鞚�鞐� 鞝勲秬 旆摑霅╇媹雼�. 瓿奠嫓鞐愲姅 霕愴暅 鞚挫爠鞐� 攵�鞐悳 RSU鞚� 旆摑鞙茧 鞚疙暣 氚滌儩頃� 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 08/08/2025鞐� 1,805欤� 氤错喌欤�毳� 欤茧嫻 $111.2491鞐� 毵る弰頃� 靷嫟霃� 氤搓碃霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 歆侅爲 氤挫湢 欤检嫕靾橂姅 RSU 攵�鞐� 頉� 28,184欤�搿� 歃濌皜頄堧嫟臧� 靹戈笀 甏�霠� 毵り皝 頉� 26,379欤�搿� 臧愳唽頄堨姷雼堧嫟.
Patrick Enright, d茅sign茅 comme administrateur de Jazz Pharmaceuticals (JAZZ), s'est vu attribuer 3 507 unit茅s d'actions restreintes (RSU) le 08/07/2025. Chaque RSU repr茅sente un droit conditionnel 脿 recevoir une action ordinaire et, sous r茅serve de la permanence du service et d'autres conditions, les unit茅s deviendront pleinement acquises le 24 juillet 2026. Le d茅p么t signale 茅galement la vente de 1 805 actions ordinaires le 08/08/2025 脿 $111,2491 pour satisfaire les obligations fiscales r茅sultant de l'acquisition d'anciennes RSU. La propri茅t茅 b茅n茅ficiaire directe d茅clar茅e est pass茅e 脿 28 184 actions apr猫s l'attribution des RSU puis est retomb茅e 脿 26 379 actions apr猫s la vente li茅e aux imp么ts.
Patrick Enright, als Direktor von Jazz Pharmaceuticals (JAZZ) gef眉hrt, erhielt am 08/07/2025 3.507 Restricted Stock Units (RSU). Jede RSU stellt das bedingte Recht dar, eine Stammaktie zu erhalten, und unterliegt fortgesetzter Dienstzeit sowie weiteren Bedingungen; die Einheiten werden vollst盲ndig am 24. Juli 2026 f盲llig. Die Meldung berichtet ferner 眉ber den Verkauf von 1.805 Stammaktien am 08/08/2025 zu $111,2491, um steuerliche Verpflichtungen aus der Aus眉bung zuvor gew盲hrter RSUs zu erf眉llen. Das gemeldete direkte wirtschaftliche Eigentum stieg nach der RSU-Zuweisung auf 28.184 Aktien und sank nach dem steuerbedingten Verkauf auf 26.379 Aktien.
FAQ
What transactions did Patrick Enright report on the JAZZ Form 4?
How many Jazz Pharmaceuticals shares does Patrick Enright beneficially own after these transactions?
When do the restricted stock units granted to Enright vest?
Why were shares sold by Patrick Enright according to the Form 4?
What is Patrick Enright's relationship to Jazz Pharmaceuticals in this filing?
